GlassScriptPhysician profile
Ailin Li
NPI 1073327177
$4,869.20
in general payments reported to CMS, 2019-2025
44 companies · $4,869 in 2025
The $4,869 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $4,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,586 · Education: $184 · Long Term Medical Supply Or Device Loan: $99.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,585.52 |
| Education | $183.98 |
| Long Term Medical Supply Or Device Loan | $99.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $847.33 | 2025 | Rybrevant, Carvykti, Erleada |
| Astrazeneca Pharmaceuticals LP | $484.84 | 2025 | Imfinzi, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $312.24 | 2025 | |
| Daiichi Sankyo INC. | $292.28 | 2025 | Datroway, Enhertu |
| Merck Sharp & Dohme LLC | $226.49 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Incyte Corporation | $218.11 | 2025 | Jakafi, Zynyz, Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $210.11 | 2025 | Fruzaqla, Ninlaro, Vpriv |
| Stemline Therapeutics INC. | $201.90 | 2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $155.89 | 2025 | Breyanzi |
| Sobi, INC | $142.35 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.73 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $106.65 | 2025 | Libtayo |
| Puma Biotechnology, INC. | $102.65 | 2025 | |
| Seagen INC. | $99.99 | 2025 | |
| Glaxosmithkline, LLC. | $92.15 | 2025 | Zejula, Jemperli, Ojjaara |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ailin Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.